Within this publication, Rosenberg and Allard cite a Therapeutics Initiative review of evidence for primary prevention statin use in 10,990 women and found no evidence supporting the claim that statin therapy reduced cardiovascular events in women. In these primary prevention trials, including ALLHAT, PROSPER, ALLHAT-LLT, ASCOTT-LLA, and AFCAPS, the review of data found no benefit for women and no decrease in overall risk of death for women, men, or seniors both with and without heart disease.
Austrian and Italian research has found that low LDL cholesterol levels, specifically in women age 50+, is directly associated with increased rates of cancer and early death.
Additionally, statin clinical trials failed to disclose all adverse events. Conclusions regarding statins and physicians' statin-prescribing choices are, therefore, based upon incomplete and seemingly unreliable data.
Have a look at Evidence for Caution: Women and Statin Use.